載入中
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
前收盤價
US$2.08
+US$0.04 · +1.96%
盤中時間採用ET。市場資料可能有所延遲。
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
日內區間
目前US$2.08
52週區間
目前US$2.08
盤中時間採用ET。市場資料可能有所延遲。
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
日內區間
目前US$2.08
52週區間
目前US$2.08
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 240.5萬 USD | 1354.47萬 USD | 635.49萬 USD | 1348.74萬 USD | 694.58萬 USD |
| 銷售、一般及管理費用 | 866.5萬 USD | 1019.81萬 USD | 901.6萬 USD | 1110.7萬 USD | 1222.11萬 USD |
| 營業費用 | 1107.7萬 USD | 2375.27萬 USD | 1744.03萬 USD | 7054.13萬 USD | 1947.8萬 USD |
| 利息收入 | 68.5萬 USD | 71.1萬 USD | 91.1萬 USD | 24.6萬 USD | 7.7萬 USD |
| 折舊和攤銷 | 7000 USD | 7000 USD | 1.1萬 USD | 12.4萬 USD | — |
| 營業利益 | −1107.7萬 USD | −2375.27萬 USD | −1744.03萬 USD | −7054.13萬 USD | −1947.8萬 USD |
| 淨利 | −779.3萬 USD | −1362.59萬 USD | −1744.16萬 USD | −5738.66萬 USD | −1226.86萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
